| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b5f41889212134f724ee94357d02f4b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A40-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2022-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d91444f23408fb0c0fe816f662d07e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_971c786af9de168358e253a1a6a8ab7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ec98d1604bd9c9522011558c1b78405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4b61c353e4f35d95b10107757b1cf57 |
| publicationDate |
2022-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022220665-A1 |
| titleOfInvention |
CD3ε-SPECIFIC ANTIBODY OF CANIDAE ANIMALS AND ANTIGEN-BINDING FRAGMENT THEREOF |
| abstract |
The present invention relates to an antibody binding specifically to the CD3ε protein of Canidae animals or an antigen-binding fragment thereof. A single-chain variable fragment (scFv) according to an embodiment of the present invention can stimulate T cells because of its excellent binding affinity for the CD3ε protein and T cells of Canidae animals and thus can be advantageously applied to the use of cancer treatment, immune activity, autoimmunity suppression. |
| priorityDate |
2021-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |